International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

A Comprehensive Study of Vaccine Safety Monitoring System: Challenges an Solution

Prof.(Dr.) Mohd.Wasiullah[1], Prof.(Dr.)Piyush Yadav[2], Mr. Mohit Vishwakarma*[3], Aroos Fatima[4]

Date of Submission: 20-04-2025 Date of Acceptance: 30-04-2025

ABSTRACT
Vaccination is a critical public health tool that provides immunity against infectious diseases by stimulating the body's immune response. Historically rooted in early practices like variolation, modern vaccines have evolved through scientific advances, including mRNA and viral vector technologies. Vaccines undergo rigorous clinical trials and ongoing monitoring to ensure safety, efficacy, and effectiveness. Various vaccine types exist—such as live-attenuated, inactivated, and subunit vaccines—each with specific administration routes. Immunization programs, guided by public health authorities, aim to reduce disease burden and promote equity. However, vaccine failures can occur due to factors related to the vaccine itself, the host, administration methods, or the pathogen. Continuous evaluation and surveillance are essential for maintaining vaccine safety and effectiveness, especially in light of emerging challenges such as antigenic variation and rare adverse events.

KEYWORDS: Vaccine Safety Monitoring**,** Adverse Events Following Immunization (AEFI)**,** Immunization Information Systems (VIS)**,** Surveillance Systems**,** Data Quality and Interoperability

I. INTRODUCTION

Infectious agents have the unique ability to trigger immunity, meaning that if someone is exposed to the same pathogen again, their body is better prepared to fight it off. This immunity is specific to infectious diseases and doesn't apply to other risks like chemicals or radiation. Throughout history, people noticed that surviving certain diseases made them less likely to get sick again, which led to the development of vaccines and vaccination practices.[1]

Before vaccines are added to public immunization programs, they undergo extensive clinical trials to ensure they're safe, stimulate an immune response, and work effectively. However, after being introduced, factors like waning immunity or rare side effects might become apparent over time, which could require adjustments to vaccination strategies.[2]Ongoing monitoring of vaccine safety, effectiveness, and coverage is essential to ensure they continue to have a positive impact on public health.

Vaccines have been key in preventing many infectious diseases and improving global health by helping the immune system recognize and fight off harmful germs. Thanks to vaccines, diseases like smallpox, polio, measles, and flu have been greatly reduced worldwide.[3]

HISTORY OF VACCINE

Immunization has been around for centuries. In the 16th century, people in India used variolation, a practice where material from smallpox sores was introduced into healthy people to help protect them from the disease. A similar method was also used in China as far back as 1000 AD.[4] The modern concept of vaccination started in 1774 when an English farmer named Benjamin Jesty used cowpox material to protect his family from smallpox. Edward Jenner took this idea further in 1796 by proving that cowpox could provide protection against smallpox. This led to the development of the smallpox vaccine, which eventually helped eradicate smallpox globally by 1980.[5]

In the late 1800s, Louis Pasteur made huge advances by creating vaccines for rabies and anthrax. The 20th century brought vaccines for diseases like diphtheria, tetanus, polio, measles, and flu. In the 1950s, new techniques using cell cultures allowed for the development of viral vaccines, like those for polio and measles.With new technology in the late 20th and early 21st centuries, vaccines like those for hepatitis B, HPV, and COVID-19 (using mRNA) were developed, marking another big leap forward in vaccine science.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

Immunization Explained

Immunization is about protecting people from diseases, usually through vaccines or antibodies.

Passive immunization involves giving someone antibodies directly, providing short-term protection, but no lasting immunity. This means the body doesn't build long-term defenses.[6]

Active immunization, on the other hand, is what most vaccines do. They train the immune system to recognize and fight off diseases, offering long-term protection. Vaccination is always a preventive measure, not a treatment for existing illnesses.

The term **vaccination** originally referred specifically to the cowpox vaccine but now includes all types of vaccines.[7] Over time, the word "inoculation" has been replaced by "vaccination."

TYPES OF VACCINE

Vaccines can be grouped based on what they contain and how they work. Here are the main types:

1. **Live-Attenuated Vaccines**: These vaccines contain a weakened form of the pathogen that can still replicate in the body, but it's not strong enough to cause illness. Examples include the MMR (measles, mumps, rubella) vaccine and the oral polio vaccine.[8]
2. **Inactivated (Killed) Vaccines**: These vaccines use pathogens that have been killed so they can't replicate, but they still trigger an immune response. Examples are the inactivated polio vaccine, the hepatitis A vaccine, and the rabies vaccine.
3. **Subunit, Protein, and Polysaccharide Vaccines**: These vaccines use specific pieces of the pathogen—like proteins or sugars—to prompt the immune system to react. Vaccines for hepatitis B, pneumococcal infections, and meningitis fall into this category.[9]
4. **Toxoid Vaccines**: These vaccines use inactivated toxins (toxins that bacteria produce) to stimulate immunity. Examples include the vaccines for diphtheria and tetanus.

In addition to these traditional types, newer vaccine technologies include:

1. **Viral Vector Vaccines**: These vaccines use a harmless virus, which is modified to carry and deliver the pathogen's antigens to the body. The Ebola vaccine and some COVID-19 vaccines (like AstraZeneca and Johnson & Johnson) are examples.
2. **mRNA Vaccines**: These vaccines work by using messenger RNA (mRNA) to tell cells in the body to produce a piece of the pathogen (like a protein).[10] This triggers the immune system to respond. Well-known examples include the Pfizer-BioNTech and Moderna COVID-19 vaccines.

Injection (Parenteral)	Intramuscular (in a muscle):	Diphtheria, tetanus, acellular pertussis
	Haemophilus influenzae:	Type b, hepatitis B, inactivated polio and meningococcalconjugate vaccines.
	Subcutaneous (under the skin):	Measles, mumps, rubella, varicella and herpeszoster vaccines.
	Intradermal (in the skin):	BCG vaccine, smallpox vaccine.
Oral (in the mouth)		Rotavirus vaccines, oral polio vaccines, some cholera and typhoid vaccines.
Intranasal (in the nose)		Live- attenuated influenza vaccine.

TABLE : 1 For some diseases, different vaccines with contrasting routes of administration .

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

Vaccine Trials and Licensure

The process of developing a new vaccine starts with identifying a clear need for it. Once early research shows promising results, clinical trials are conducted to ensure the vaccine is safe and effective. These trials are carried out using batches produced under strict quality standards and generate the data needed for regulatory approval. Vaccine trials are divided into four phases, each with its own specific goals and design.[11]

VACCINE TRIAL PHASE

Before a vaccine is approved for general use, it undergoes a series of clinical trials to assess its safety, ability to stimulate an immune response (immunogenicity), and overall effectiveness (efficacy). These trials follow the same procedures as other clinical studies and are closely monitored by health authorities around the world.

- **Phase I Trials**: The first stage of human testing, usually involving a small group of healthy adult volunteers. The primary focus is on evaluating safety.
- **Phase II Trials**: These trials are conducted on the target population (e.g., children), often with a few hundred participants. The goal is to assess safety further and measure immune responses to different doses or vaccine candidates.[12]
- **Phase III Trials**: Large-scale trials involving tens of thousands of people to evaluate both safety and effectiveness.
- **Post-licensure Studies (Phase IV Trials)**: After the vaccine is approved, Phase IV trials continue to monitor its performance in the general population.[13] These are not experimental like earlier phases but focus on ongoing safety and effectiveness monitoring

Phase II and III trials are typically **double-blind, randomized controlled trials**. Participants are randomly assigned to receive either the vaccine or a placebo (or sometimes an existing vaccine), and neither they nor the researchers know which group they belong to. The goal is to see if the new vaccine performs better (superiority study) or at least as well (non-inferiority study) as current treatments, while possibly offering other benefits like fewer side effects or lower cost

Participants are carefully selected based on strict criteria, and their health is closely monitored throughout the trial to meet regulatory standards. In recent years, **adaptive trial designs**, which combine different trial phases into one study, have become more common.

The whole vaccine development process typically takes over 10 years, but in urgent situations like the Ebola or COVID-19 outbreaks, this timeline was accelerated.[14]

Vaccine manufacturing

Vaccine production started in the early 19th century, with individual researchers, some of whom made vaccines for commercial use. By the early 20th century, the first companies focused solely on vaccine production were established, alongside public health institutes that also began manufacturing vaccines.

However, making vaccines is more costly and requires a larger investment compared to other pharmaceutical products, mainly because of stricter regulations.[15] This has made it harder for smaller companies and public health organizations to produce vaccines on their own.[16]

Today, the global vaccine market is largely controlled by four big pharmaceutical companies. GlaxoSmithKline (GSK), Merck, Pfizer, and Sanofi. From a public health standpoint, this for smaller or less profitable markets. Moreover, reduced competition has led to higher vaccine prices.

VACCINATION PROGRAM

The main goal of vaccination is to reduce illness and mortality from vaccine-preventable diseases and promote health equity.[17]A structured vaccination program is more efficient and safer than simply making vaccines available. It includes clearly defined goals, strategies, operational frameworks, and monitoring methods. Successful vaccination programs are provided free of charge as part of a coordinated public health initiative. These programs include guidelines, vaccination coverage goals, disease control targets, and systematic monitoring of program effectiveness and safety. The term "vaccination programme" can refer to multi-vaccine or single vaccine programs, with governments typically implementing these programs at the national or regional level.[18]

History of vaccination programmes

The first recorded use of vaccination occurred in the 18th century for military purposes, focusing on preventing smallpox outbreaks among soldiers. Subsequent efforts were also aimed at

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

military personnel. Civilian vaccination programs emerged in Europe and North America in the early 19th century to control smallpox. By the 1950s, Western countries introduced routine vaccination programs against poliomyelitis, diphtheria, and tetanus, marking the beginning of structured national immunization efforts. By 2018, most countries had incorporated at least nine or more vaccine antigens into their national immunization schedules. International vaccination programs are required for disease eradication, with smallpox being the only vaccine-preventable disease to have been successfully eradicated.[19]

MONITORING AND EVALUATION OF VACCINATION PROGRAMMES

Vaccination programmes offer significant benefits at individual and population levels, improving public health. However, they can also have unintended effects. Continuous monitoring of benefits and risks is crucial throughout the program's lifespan.[20] Key areas and tools are outlined in Table 2, aiming to sustain or adapt the programme to maximize benefits while minimizing risks.

The monitoring and evaluation of vaccination programmes involve various stakeholders, including governments, public health authorities, regulatory agencies, and vaccine manufacturers. Governments and public health authorities are responsible for implementing and funding vaccination programs, ensuring their safety and effectiveness. Regulatory agencies, such as the European Medicines Agency and the US Food and Drug Administration, oversee vaccine market authorization and safety assessments. They can require manufacturers to conduct additional safety studies and evaluate pharmacovigilance and risk management plans. Manufacturers, also known as marketing authorization holders, monitor vaccine benefits, safety, and overall benefit-risk profiles.[21]They are legally required to assess the effectiveness and safety of their licensed vaccines and report any suspected adverse reactions to regulatory authorities. Academic epidemiologists and international networks are key in conducting epidemiological studies on vaccines and vaccination programmes, relying on data from multiple studies across different countries.

Vaccine safety

Vaccines are not entirely risk-free medicines, but they are administered to healthy individuals as a preventive measure at a population level, reinforcing the ethical principle of primum non nocere. Scientist Maurice Hilleman, responsible for developing over 40 vaccines, famously stated that he never breathed a sigh of relief until the first 3 million doses were out there. Large-scale clinical trials are not sufficient to detect rare or uncommon adverse events following immunization (AEFI).[22] The post-licensure phase is where most information about rare and uncommon AEFI is gathered, particularly regarding vaccine safety in diverse populations, including those excluded from clinicaltrials. The unprecedented speed and scale of COVID-19 vaccine deployment made it essential to quickly detect and investigate potential safety concerns. Confirmed safety signals include Vaccine-Induced Thrombosis and Thrombocytopenia (VITT) associated with some adenoviral vector vaccines and myocarditis linked to mRNA vaccines. The detection and reporting of AEFI also depend on the data systems used in vaccine safety surveillance [23]

The safety of COVID-19 vaccines has been a challenge due to various factors, including vaccine-related, pandemic-related, and response-related factors. Vaccine-related factors include the use of new technologies like mRNA and adenoviral vector vaccines, the introduction of novel adjuvants, and concerns about vaccine-associated enhanced disease(VAED).

Pandemic-related factors include the widespread SARS-CoV-2 infection, which could lead to mistaken infections in recently vaccinated individuals. Response-related factors include emergency-use authorizations, shorter follow-up times, increased administration errors, and public perceptions of AEFI.[24]Clinicians play a crucial role in identifying new or rare AEFI, which are confirmed through vaccine surveillance systems. For example, VITT and myocarditis were first detected by specialist hematologists and cardiologists, leading to further investigation and public health actions.[25]

Factor leading to immunization factor

Immunization failure occurs when a vaccine does not provide the expected protection against a disease. This failure can be classified into **primary vaccine failure** (when the immune system fails to respond to the vaccine) or **secondary vaccine failure** (when immunity wanes over time). Several factors contribute to vaccine failure, categorized into **vaccine-related, host-related, and administration-related factors**.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

1 . Vaccine-Related Factors

a. Improper Storage and Handling

- Many vaccines require specific temperature conditions (usually **2°C–8°C**). Exposure to heat, freezing, or light (for light-sensitive vaccines like BCG and MMR) can degrade the vaccine.[26]
- Cold chain failures during transportation or storage reduce vaccine potency.

b. Expired or Contaminated Vaccines

- Expired vaccines may lose their effectiveness, leading to failure.
- Contamination (due to improper handling) may alter the vaccine's composition or cause infections instead of immunity.[27]

2. Host-Related Factors

a. Age and Immune System Maturity

- **Neonates and infants** may have immature immune systems or maternal antibodies that neutralize the vaccine before it induces immunity (common with measles or pertussis vaccines).
- **Elderly individuals** may have weakened immune responses, leading to reduced vaccine effectiveness (e.g., influenza and COVID-19 vaccines).[28]

b. Genetic Factors

- Some individuals may have genetic variations affecting their immune response to vaccines (e.g., HLA genes).
- Ethnic and racial differences can influence vaccine response due to genetic diversity.

Challenges and solution

Vaccine safety concerns can arise when there is a perceived increase in known adverse events (AEFI) or when a new type of adverse event is reported for the first time. The Brighton Collaboration and the Coalition for Epidemic Preparedness Innovations (CEPI) Safety Platform for Emergency Vaccines (SPEAC) Project compiled a list of Adverse Events of Special Interest (AESI) before the COVID-19 vaccine rollout.[29]These AESI were chosen based on their previous association with vaccination, experience with similar vaccine platforms, or potential link to complications of the targeted disease. Distinguishing between a genuine vaccine safety signal and a coincidental event requires robust surveillance and clinical follow-up. A safety signal in pharmacovigilance is defined as reported information on a possible causal relationship between an adverse event and a drug, previously unknown or incompletely documented.The process of safety signal management involves several steps: signal detection, signal validation, and signal investigation.[30]

Spurious report

The global public health challenge of vaccine hesitancy has led to false reports of deaths or severe illnesses, especially on social media. These misleading claims can erode public confidence in vaccines and negatively impact vaccination programs, potentially triggering reposts or similar claims mistakenly identified as safety signals.

Politics and social media

Political polarization has led to an increase in anti-vaccine rhetoric, particularly among mainstream political figures who often use social media to share their views. This has amplified vaccine skepticism.[31]Healthy recipients, such as pregnant women and immunosuppressed individuals, are more likely to accept COVID-19 vaccines when not pregnant due to safety concerns. Routine pharmacovigilance for these groups is challenging, as many surveillance systems do not reliably track pregnancy status and few can link maternal vaccination to infant health outcomes.

Solicited surveillance

Solicited surveillance is a widely used method in COVID-19 vaccine rollouts, including V-SAFE, Yellow Card Vaccine Monitor, and usVaxSafety. These systems collect comprehensive demographic data and send follow-up messages to vaccine recipients at specific intervals. If a recipient reports an adverse events (AEFI), they can provide categorized responses about local or systemic reactions, allowing for automated calculations of reaction rates.[32] These results are then compared with clinical trial data to assess consistency or potential concerns. Subgroup analysis allows monitoring of high-risk groups, such as pregnant individuals, and provides publicly available data visualizations.

Solicited surveillance plays a critical role in assessing common short-term AEFI, providing early data for public health communication, and boosting public confidence by monitoring vaccine safety in real-time. However, these systems have limitations, such as smaller sample sizes, declining response rates over time, and only including individuals who respond to messages.[33]Despite

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

these challenges, solicited surveillance remains an essential tool for characterizing vaccine reactogenicity and informing public health decisions.[34]

Overcoming the challenges

Automated data exchange between VIS and other healthcare systems can address issues faced by healthcare professionals by establishing standardized data formats. Data standards are documented agreements that define data representation, format, and recording rules to maintain uniformity across different sources.[35] Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR) is a widely used international interoperability standard that defines how health information is structured and exchanged between systems. FHIR divides health records into modular components called "resources" that can be extracted and reused. It is flexible, requiring no specific programming language, and is well-suited for internet-based technology and mobile applications. Integrating HL7 FHIR between VIS and other health systems has been shown to enhance immunization data quality and improve efficiency in vaccination record management.[36]

Data quality

High-quality immunization data is crucial for effective vaccination program management. Data quality is assessed based on three criteria: completeness, timeliness, and accuracy. Challenges in data quality include inadequate validation processes, lack of data quality control, missing reports, duplicate or incomplete vaccination records, delayed data entry, and incorrectly stored information. Adult vaccination records are particularly problematic, as reporting for adults is often not mandatory[37]

Maintaining up-to-date contact information is another common problem in VIS data quality. In order to address these challenges, an ideal VIS should include vaccination data from all healthcare facilities, including public and private facilities.[38] Improving timeliness is essential to reduce delays and prevent missed reporting, especially during outbreaks or emergencies. Ensuring accuracy is also crucial. Various countries have adopted alternative methods to improve accuracy, such as Spain using barcode scanning to input vaccination data into VIS, 15 countries using dropdown menus for healthcare providers to select vaccines, Finland and Hungary linking VIS data to product databases for automatic updates, and Belgium integrating VIS with electronic medical records via a web service. These approaches have helped improve data quality, reduce errors, and ensure more efficient immunization record management across different countries.[39]

Usability

The implementation of VIS has faced several usability challenges, such as system operation difficulties, limited access to adult vaccination records, lack of developer support, inability to adapt to user needs, failure to input past records, inability to generate reports or track vaccine accountability, poor integration with other healthcare systems, manual data entry without automation, slow, sometimes non-functional web interfaces, and inability to perform specific functions as required by users. To improve user experience and functionality, developers should involve users in the design, development, and updates of VIS, ensure the system is user-friendly, efficient, and designed for high acceptance, and implement a monitoring mechanism to resolve issues promptly.[40]

Government regulation

The European Medicines Agency (EMA) emphasizes the importance of VIS in monitoring vaccine benefits and risks, requiring timely data collection. However, challenges such as VIS ownership issues and lack of government support for implementation have been identified. The government's role is crucial in ensuring high-quality immunization data collection. In countries with low healthcare provider participation, legislation can be introduced to mandate immunization recording. Research suggests that regulations can increase documented vaccination records. Most European countries have government-owned VIS, as evidenced by the 2016 ECDC survey. Government ownership is essential for effective VIS management.[41]

Current trend and future prospective in vaccine safety monitoring

Vaccine safety monitoring has become a critical aspect of public health, particularly after the rapid development and deployment of COVID-19 vaccines. Current trends emphasize the use of real-time surveillance systems, artificial intelligence (AI), and big data analytics to detect adverse events more efficiently.[42]Traditional passive

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

surveillance systems, such as the Vaccine Adverse Event Reporting System (VAERS) in the U.S., have been supplemented with active monitoring approaches like the Vaccine Safety Datalink (VSD) and the Global Vaccine Safety Initiative (GVSI). AI-driven algorithms are being used to analyze vast datasets, identifying potential safety concerns faster than manual methods. Social media and digital platforms are now being leveraged to track vaccine-related discussions, providing early signals of adverse reactions and public concerns.[43]

However, several challenges persist, such as underreporting of adverse events in passive surveillance systems, public mistrust in vaccines, ethical concerns related to data privacy and security, and global disparities in vaccine safety monitoring infrastructure. Standardizing reporting mechanisms across different countries remains a complex issue, making international collaboration essential for a more comprehensive approach to vaccine safety. Future perspectives focus on enhancing proactive monitoring through blockchain technology, machine learning, and more integrated global surveillance networks. However, challenges like data privacy, misinformation, and infrastructure disparities must be addressed for these systems to be fully effective [44]

II. CONCLUSION

The advancements in vaccine safety surveillance, driven by the information revolution, have significantly enhanced the detection and monitoring of adverse events following immunization (AEFI). The integration of modern technologies, such as web-based reporting, business-intelligence systems, and active surveillance, has improved data collection and analysis, strengthening public confidence through real-world safety data. However, challenges remain, particularly in the areas of interoperability, data quality, security, and privacy. Addressing these obstacles, alongside expanding citizen engagement and improving infrastructure, is essential to the continued success of vaccine information systems (VIS). Furthermore, expanding the scope of VIS to include adult immunization records and addressing barriers faced by citizens in utilizing these systems will be key to optimizing global vaccine safety efforts. By overcoming these challenges, we can ensure that vaccine safety systems remain effective, reliable, and trusted by communities worldwide, contributing to enhanced public health outcomes across diverse populations.

REFERENCES

[1]. Boylston, A. (2012). The origins of inoculation. Journal of the Royal Society of Medicine, 105(7), 309– 313. doi:10.1258/ jrsm.2012.12k044.

[2]. Plotkin, S. A., Orenstein, W. A., Offit, P. A., & Edwards, K. M. (Eds.) (2018). Plotkin's vaccines (7th ed.). Philadelphia, PA: Elsevier.

[3]. Farrington, P., & Miller, E. (2003). Clinical trials. In A. P. Robinson, M. P. Cranage, & M. J. Hudson (Eds.), Methods in molecular medicine: Vaccine protocols (pp. 335– 351). Totowa, NJ: Humana Press.

[4]. Halloran, M. E., Longini, I. M., &Struchiner, C. J. (2010). Design and analysis of vaccine studies. New York: Springer.

[5]. Hennock, E. P. (1998). Vaccination policy against smallpox, 1835– 1914: A comparison of England with Prussia and imperial Germany. Social History of Medicine, 11(1), 49– 71.doi:10.1093/ shm/ 11.1.49.

[6]. Cherian, T., & Mantel, C. (2020). National immunization programmes. BundesgesundheitsblattGesundheitsforschungGesundheitsschutz, 63(1), 16– 24. doi:10.1007/ s00103- 019- 03062- 1.

[7]. Rennels, M. B., Parashar, U. D., Holman, R. C., Le, C. T., Chang, H., & Glass, R. (1998). Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatric Infectious Disease Journal, 17(10), 924–925.

[8]. Murphy, T. V., Gargiullo, P. M., Massoudi, M. S., Nelson, D. B., Jumaan, A. O., Okoro, C. A.,… Livingood, J. R. (2001). Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine, 344, 564–572.

[9]. Kurth R. [Infectious diseases: how big is the real danger? Interview by Strehlow Karen. Dtsch Med Wochenschr. 2005;Suppl 1:64–65.

[10]. Buttery JP. Developing standard safety outcomes for COVID-19 vaccines. Vaccine. 2021;39(22):3025–3027. doi:10.1016/j.vaccine.2021.03.004.

[11]. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2433-2442 www.ijprajournal.com ISSN: 2456-4494

Thrombotic Thrombocytopenia after ChAdox1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. doi:10.1056/NEJMoa2104840.

[12]. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund- Johansen F, Ahlen MT, Wiedmann M, Aamodt A-H, Skattør TH, Tjønnfjord GE, et al. Thrombosis and Thrombocytopenia after ChAdox1 nCov-19 vaccination. N Engl J Med. 2021;384 (22):2124–2130. doi:10.1056/NEJMoa2104882.

[13]. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Levi N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med 2021 N Engl J Med; 385:2140–49. doi: 10.1056/ NEJMoa2109730.

[14]. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US Military. JAMA Cardiol. 2021;6 (10):1202–1206. doi:10.1001/jamacardio.2021.2833.

[15]. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475.

[16]. Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Völker U, et al. Insights in ChAdox1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021;138(22):2256–2268. doi:10.1182/blood.2021013231.

[17]. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–2139. doi:10.1056/NEJMoa2110737.

[18]. Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, Hunt D, Mei XW, Dixon S, Zaccardi F, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27(12):2144–2153. doi:10.1038/s41591-021-01556-7.

[19]. Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, et al. Consensus summary report for CEPI/BC March 12–13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020;38(31):4783–4791. doi:10.1016/j.vaccine.2020.05.064.

[20]. Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115–2122. doi:10.1016/S0140-6736(09)61877-8.

[21]. VIII CIOMS Working Group. Practical aspects of signal detection in pharmacovigilance. Geneva: The Council For International Organizations Of Medical Sciences; 2010.

[22]. Berry JG, Gold MS, Ryan P, Duszynski KM, Braunack-Mayer AJ. Vaccine assessment using Linked Data Working G. Public perspectives on consent for the linkage of data to evaluate vaccine safety. Vaccine. 2012;30(28):4167–4174. doi:10.1016/j.vaccine.2012.04.056.

[23]. World HealthOrganization. Safety of medicines : a guide to detecting and reporting adverse drug reactions : why health professionals need to take action. Report No.: WHO/EDM/QSM/2002.2; Geneva; 2002.

[24]. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, Geelhoed GC, Mascaro F, Scully M, Weeramanthri TS, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011;1(1): e000016. doi:10.1136/bmjopen-2010-000016.

[25]. Gold MS, Effler P, Kelly H, Richmond PC, Buttery JP. Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia. Med J Aust.

2010;193(9):492–493. doi:10.5694/j.1326-5377.2010.tb04029.x.

[26]. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023–1034. doi:10.1016/S0140-6736(21)00306-8.

[27]. ABCFC. As younger children become eligible for the vaccine, anti-vaxxers spread false information about deaths. ABC News: ABC; 2022 [accessed 2022 Jan 28].

[28]. Cassidy C 'Utter fear': Gold Coast GP receives death threats from 'anti-vaxxers' after false claim of child vaccine deaths. The Guardian. 2022 [accessed 2022 Feb 1].

[29]. Sharfstein JM, Callaghan T, Carpiano RM, Sgaier SK, Brewer NT, Galvani AP, Lakshmanan R, McFadden SM, Reiss DR, Salmon DA, et al. Uncoupling vaccination from politics: a call to action. Lancet. 2021;398(10307):1211–1212. doi:10.1016/S0140-6736(21)02099-7.

[30]. Germani F, Biller-Andorno N, Lavorgna L. The anti-vaccination infodemic on social media: a behavioral analysis. PLoS One. 2021;16(3):e0247642. doi:10.1371/journal.pone.0247642.

[31]. Sharfstein JM, Goodman JL, Borio L. The US regulatory system and COVID-19 vaccines: the importance of a strong and capable FDA. Jama. 2021;325(12):1153–1154. doi:10.1001/jama.2021.1961.

[32]. Skirrow H, Barnett S, Bell S, Riaposova L, Mounier-Jack S, Kampmann B, Holder B. Women's views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: a multi-methods study in the UK. BMC Pregnancy Childbirth.2022;22(1):33. doi:10.1186/s12884-021-04321-3.

[33]. Clothier HJ, Crawford NW, Russell M, Kelly H, Buttery JP. Evaluation of 'SAEFVIC', a pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf. 2017;40 (6):483–495. doi:10.1007/s40264-017-0520-7.

[34]. Gidudu JF, Shaum A, Dodoo A, Bosomprah S, Bonsu G, Amponsa-Achiano K, Darko DM, Sabblah G, Opare J, Nyaku M, et al. Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana. Vaccine. 2020;38 (5):1009–1014. doi:10.1016/j.vaccine.2019.11.050.

[35]. Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum VaccinImmunother. 2014;10 (12):3726–3730. doi:10.4161/hv.34369.

[36]. Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT. Post-Licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015. Vaccine. 2018;36(13):1781–1788. doi:10.1016/j.vaccine.2018.02.034.

[37]. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007;26(11):979–984. doi:10.1097/INF.0b013e318149dfea.

[38]. Mesfin YM, Cheng A, Lawrie J, Buttery J. Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review. BMJ Glob Health. 2019;4(4):e001065. doi:10.1136/bmjgh-2018-001065.

[39]. Crawford NW, Clothier H, Hodgson K, Selvaraj G, Easton ML, Buttery JP. Active surveillance for adverse events following immunization. Expert Rev Vaccines. 2014;13(2):265–276. doi:10.1586/14760584.2014.866895.

[40]. Costa MA, Huang SS, Moore M, Kulldorff M, Finkelstein JA. New approaches to estimating national rates of invasive pneumococcal disease. Am J Epidemiol. 2011;174(2):234–242. doi:10.1093/aje/kwr058.

[41]. Van Holle L, Zeinoun Z, Bauchau V, Verstraeten T. Using time-toonset for detecting safety signals in spontaneous reports of adverse events following

immunization: a proof of concept study. Pharmacoepidemiol Drug Saf. 2012;21(6):603–610. doi:10.1002/pds.3226.

[42]. Lo Re V 3rd, Klungel OH, Chan KA, Panozzo CA, Zhou W, Winterstein AG. Global covid-19 vaccine rollout and safety surveillance-how to keep pace. Bmj. 2021;373:n1416.

[43]. Deeks SL, Clark M, Scheifele DW, Law BJ, Dawar M, Ahmadipour N, Walop W, Ellis CE, King A. Serious adverse events associated with BacilleCalmette-Guérin vaccine in Canada. Pediatr Infect Dis J. 2005;24(6):538–541. doi:10.1097/01.inf.0000164769.22033.2c.

[44]. Glover C, Crawford N, Leeb A, Wood N, Macartney K. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxsafety. Vaccine. 2020;38(31):4892–4900. doi:10.1016/j.vaccine.2020.04.056.